2027 Speaker Biographies



Alexej Abyzov, PhD, Professor of Biomedical Informatics, Mayo Clinic
Professor of Biomedical Informatics
Mayo Clinic
Dr. Alexej Abyzov completed his undergraduate and master’s studies at the Moscow Institute of Physics and Technology in 2002 and subsequently earned his PhD in Computational Biology from Northeastern University in 2008. Prior to joining Mayo Clinic in 2014, he was a postdoctoral fellow and research scientist at Yale University, where he pioneered approaches for detecting genomic structural variations from sequencing data and demonstrated the detection of somatic mutations in individual human cells. Dr. Abyzov is currently a Professor at Mayo Clinic, where he leads a computational genomics laboratory focused on human genomics, somatic mosaicism, and the development of computational approaches for detecting and characterizing genomic variation. His research integrates computational genomics, single-cell technologies, and large-scale sequencing to investigate somatic mutations and their roles in human development, aging, and disease.
Jason Alexander, CEO & Co-Founder, ChiefAI
CEO & Co-Founder
ChiefAI
Jason Alexander is the Founder and CEO of ChiefAI, a business management and AI advisory firm focused on helping organizations adopt AI in a practical, measurable way. He works directly with leadership teams to cut through the noise of emerging technologies, align AI initiatives with real business goals, and redesign workflows to drive efficiency, growth, and margin improvement. With over 20 years of experience in staffing, recruiting, and revenue operations, Jason previously served as Co-Founder and Chief Revenue Officer of BANKW Staffing, where he helped scale the organization from startup to over $100 million in revenue. His career has been defined by building high-performing teams, implementing disciplined operational strategies, and driving sustainable growth across competitive markets. At ChiefAI, Jason has pioneered an “outsourced Chief AI Officer” model, giving companies access to executive-level AI strategy, implementation, and governance without the need for internal specialization. His approach emphasizes clarity over complexity, focusing on where AI can deliver immediate impact inside sales, recruiting, operations, and customer workflows. Jason is a recognized speaker and advisor on AI adoption, workforce transformation, and the future of work. He is known for his direct, practical perspective and his belief that AI success is not about tools, but about how work gets done.
Saeed Amal, PhD, Research Professor, Bioengineering Department, The Roux Institute and The Institute for Experiential AI, Northeastern University
Research Professor
Northeastern Univ
Prof. Saeed Amal is a Research Professor at the department of bioengineering at Northeastern University. Amal is a member of The Roux Institute and The Institute for Experiential AI. Amal was a Postdoctoral Fellow at the Stanford University School of Medicine where he focused on the applications of artificial intelligence to improve healthcare, specifically care for cardiovascular disease. He received his PhD and MSc degree in Computer Science from the University of Haifa and a BSc degree in Computer Science from Technion. Amal has vast leadership experience in applied research from the tech industry and is a former VP of an R&D data medical startup in the field of cardiology. His research interests are the healthcare applications for artificial intelligence, including deep learning and machine learning, natural language processing (NLP), image processing, and recommender systems.
Rody Arantes, Director, Digital Technology, Montai Therapeutics
Director of Digital Technology
Montai Therapeutics Inc.
Rody Arantes is the Director of Digital Technology at Montai Therapeutics, where he leads the strategy and execution of the company’s digital ecosystem spanning scientific compute, data governance, and GxP-aligned platform engineering. With a career that bridges biotech, defense, and large-scale web infrastructure, Rody specializes in transforming complex scientific and operational requirements into scalable, secure, and interoperable systems. He is known for building high-performing teams, driving cross-functional innovation, and developing digital foundations that enable organizations to move faster with confidence.
Naveed Aziz, MPhil, PhD, EMBA, Chief Data Officer, Genome Canada
Chief Data Officer
Genome Canada
Dr. Naveed Aziz is Chief Data Officer at Genome Canada, where he leads the organization's data strategy, governance, and its position across national and international data ecosystems. Over more than twenty years in genomics, his work has moved from lab bench science to the infrastructure, policy, and partnerships that let genomic data function as a national asset rather than a research byproduct. Naveed designed and led the launch of the Canadian National Precision Health Initiative (CPHI), a $200 million program to sequence 100,000 whole genomes across twelve cohort institutions and give Canada a coordinated path toward data-driven, equitable healthcare. That work led directly to his appointment as Chief Data Officer. He now sets Genome Canada's broader data strategy. Before this role, Naveed was CEO of CGEn, Canada's national genome sequencing platform, where he helped build the organization from the ground up into a core part of the country's genomics infrastructure. He also served as Genome Canada's Director of Technology Programs, and started his leadership journey at York University, where he built a genomics lab, turning early-stage science into working infrastructure and a future legacy. He has represented Canada on international genomics and data policy committees, including the UK Ministry of Science and Innovation and the Organisation for Economic Co-operation and Development. His work has been recognized with the Canadian Association of Research Administrators' 2022 Research Partnership Award. In 2018, adMare BioInnovations and Pfizer named him one of Canada's Emerging Executive Leaders. He was profiled among Canada's Top 20 Dynamic CEOs in 2021. Naveed holds a PhD in Gene Targeting from the University of Dundee, earned through the Commonwealth Fulbright Scholarship program, and a Master of Philosophy in Biotechnology from Quaid-i-Azam University in Islamabad. He also holds an Executive MBA from the Bradford School of Management. He completed a research fellowship at the Noble Research Institute in the United States and later finished the executive training program at Harvard Business School.
Carole Baas, PhD, National Patient Advocate, Physical Sciences in Oncology Network, National Cancer Institute (NCI)
National Patient Advocate, Physical Sciences in Oncology Network
National Cancer Institute (NCI)
Gregory J. Baker, PhD, PharmD, Assistant Professor, Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University
Assistant Professor
Oregon Health & Science University
Dr. Baker is a cancer systems immunologist at the OHSU Knight Cancer Institute with an interdisciplinary background in experimental and computational biomedical research. His research interest lies in connecting immune and metabolic changes within the tumor microenvironment to the status of the peripheral immune system and its variation across subjects. As a postdoctoral fellow at Harvard Medical School, his work centered on developing and deploying research strategies for correlative clinical and preclinical studies in cancer immunology. These included multiplex tissue imaging methods, such as CyLinter and MORPHAEUS, and SYLARAS, an experimental method for systemic immune response profiling.
Joe Barrows, Director, Natera, Inc.
Senior Director, Software Engineering, Production Bioinformatics
Natera Inc
I have broad experience in software engineering, bioinformatics, biotechnology project management, and medical sales. At Natera, I lead software engineering for production bioinformatics pipelines. I am also a member of the Industry Advisory Board at Johns Hopkins University Center for Biotechnology Education. Before joining Natera, I led software engineering, bioinformatics, cybersecurity, project management, and HIPAA compliance at Biotia, an infectious disease and artificial intelligence startup. At Sema4 (formerly the Icahn School of Medicine at Mount Sinai, now GeneDx), I managed a team that built cloud scientific computing pipelines and project managed New York State Department of Health regulatory submissions of next-generation sequencing-based diagnostic tests. Prior to Sema4, I sold molecular diagnostic testing to physicians for Counsyl (now Myriad Women's Health). I started my career at VWR International (now part of Avantor), where I sold laboratory supplies and equipment to scientific researchers at major research institutes in the Washington, D.C. metropolitan area. I have a B.S. in Chemistry with a minor in Italian from Georgetown University, an M.S. in Bioinformatics from Johns Hopkins University, and an M.B.A. in Healthcare and Technology Management from New York University Leonard N. Stern School of Business. I am a Certified HIPAA Privacy and Security Expert (CHPSE).
Joseph Batchelor, PhD, Head of Structural Biology, US Biologics Research, Sanofi Group
Head of Structural Biology
Sanofi
Dr. Joseph Batchelor is Head of Structural Biology for US Large Molecule Research at Sanofi, where he leads efforts to enable structure-guided design across biologics programs. Since joining Sanofi in 2013, he has pioneered the integration of cryo-electron microscopy into the company’s discovery workflows, establishing a hybrid internal–external cryo-EM platform that delivers high-resolution structures for challenging targets. Trained as a crystallographer, Joseph transitioned to cryo-EM in 2016 and has since advanced structural biology capabilities to support non-crystallizable systems. In recent years, his team has focused on integrating structure-enabled AI workflows into protein engineering pipelines. He earned his Ph.D. from the University of California, Berkeley, and completed postdoctoral training at Washington University School of Medicine.
Merima Birkhimer, Scientific Product Lead, Computational Sciences Center of Excellence, Genentech, Inc.
Scientific Product Lead
Genentech Inc
Merima Birkhimer is Scientific Product Lead at Genentech, where she develops data product strategy and drives the delivery of data capabilities that support AI-driven therapeutic discovery and development. Her work focuses on making complex scientific data accessible and actionable in modern research environments and building the data foundations for AI-enabled workflows. Her recent work centers on scientific data sourcing and the delivery of AI-native data product bundles that contextualize canonical scientific data to support reasoning by agentic workflow systems for target identification and assessment.
Mohan Boggara, PhD, Digital Transformation Leader, CMC Process Development & Data Sciences, Sanofi
Digital Transformation Leader
Sanofi
Mohan Boggara is currently Digital Transformation Leader working to enable Full Transformation within the CMC Process Development at Sanofi. Prior to this Mohan has spent several years at Amgen as a Scientist/Data Scientist in Drug Product Process Development as well as in Manufacturing & Supply. He has also led major Digital programs. He is a Chemical Engineer with PhD from University of Houston and years of postdoctoral experience from Rensselaer Polytechnic Institute & Rice University
Jordan Brayanov, VP, Enterprise AI & Digital Strategy, Kiniksa Pharmaceuticals
Senior Director, Digital Strategy
Kiniksa Pharmaceuticals
Jordan Brayanov, PhD is a Senior Director, Digital Strategy, within the Data Sciences Institute at Takeda Pharmaceuticals. In this role, he oversees the strategic development and deployment of Digital Health Solutions within clinical programs across the R&D organization. Prior to joining Takeda, Jordan served as Vice President of Research at Respiratory Motion -- a leader in respiratory volume monitoring. He was responsible for the clinical research, product research, and product development of a fundamentally new measurement modality. His experience and research focus are on the design and development of patient-centric tools and measurement equipment, advanced data modeling, and data visualization. Jordan holds a PhD in Computational Neuroscience from Harvard University, as well as an MS in Mechanical Engineering along with dual BS degrees in Mechanical Engineering and Electrical Engineering and Computer Science from MIT.
Ben Busby, PhD, Global Alliances Manager, Omics, NVIDIA
Global Alliances Manager, Omics
NVIDIA
Ben Busby, PhD, is a renowned leader in biomedical informatics, computational biology, and interdisciplinary data science. With a career spanning academia, industry, and government, he is dedicated to making biomedical data science a more productive and collaborative environment for bioinformaticians and data scientists. Dr. Busby currently serves as Senior Alliances Manager, Genomics at NVIDIA, where he drives strategic collaborations and innovations in genomics, AI, and biomedical research. He is also an Adjunct Faculty Member in the Computational Biology Department at Carnegie Mellon University, contributing to cutting-edge research and education. Prior to his role at NVIDIA, Dr. Busby was a Principal Scientist at DNAnexus, where he prototyped scientific data integration solutions and built complex compute environments for users of the UK BioBank and other major biomedical research initiatives across academia, industry, and government. He also led prototype software development in machine learning, omics, imaging, pharmacogenomics, and natural language processing (NLP), often through global hackathons that he organized and participated in. Prior to DNAnexus, Ben consulted for Johns Hopkins University, Ariel Precision Medicine, Deloitte, and NCBI, as well as founding the Bioinformatics and Data Science department at the FAES Graduate School on the NIH campus.His expertise spans biomedical informatics, deep learning, interdisciplinary collaboration, AI-driven knowledge graphs, and computational biology. He holds a PhD in Biochemistry from the University of Maryland, Baltimore, and an undergraduate degree in Biochemistry from the University of Maryland, Baltimore County.
Lawrence Callahan, PhD, Chief Scientist, Autopoiesis Sciences
Chief Scientist
Autopoiesis Sciences
Dr. Larry Callahan is currently the Chief Scientist at Autopoiesis Sciences, a recently founded scientific, health care related AI firm. Autopoiesis Science developed Aristotle an AI-co-scientist that outperformed all of the leading AI agents in standardized accuracy tests (https://autopoiesis.science/). Larry graduated from University of Chicago with a Ph.D. in chemistry. Larry’s work spans nucleic acid chemistry, HIV research, the development of analytical methods for biotechnology-derived products and the development of a number of scientific information resources at NIH. He has held pivotal roles at the FDA, NIH, and the United States Pharmacopeia, where his innovations have advanced research infrastructure and improved standards in pharmaceutical science. Larry is the primary editor of the IDMP ISO11238 substance standard and was responsible for the development of the Global Substance Registration System (GSRS). Larry is currently the platform lead for the development of the Global Substance Knowledge System (GSKS) which will integrate the Aristole’s co-Scientist into the GSRS. The GSKS is intended to enhance drug discovery, clinical studies, regulatory submissions, the global supply chain and medication management.
Madeleine Carbonneau, Graduate Student, Biostatistics, Harvard University
Graduate Student
Harvard Univ
Madeleine Carbonneau is a PhD student in Biostatistics at Harvard University. Her research uses statistical methods to study molecular aging and its connections to health, including cardiovascular disease. She previously worked as a postbaccalaureate fellow at the National Heart, Lung, and Blood Institute, where she studied DNA methylation and cardiovascular health. Madeleine earned an AB in Applied Mathematics from Harvard College and teaches statistical modeling at the Harvard T.H. Chan School of Public Health.
Anastasia Christianson, PhD, Pharma Industry Data Science Leader
Pharma Industry Data Science Leader
Strategic, visionary leader with an established track record of building and leading multidisciplinary, global Informatics and IS/IT teams, driving change and simplification and delivering value through innovation. Over 20 years’ experience in the biotechnology and pharmaceutical industry working in both Discovery and Development leading projects, managing complex portfolios, driving change programs, identifying opportunities for strategic initiatives, and translating scientific and medical questions into innovative solutions. Areas of particular strength include: strategy development and implementation, translational medicine, biomedical and health informatics, evidence-based decision makings, data and decision science, and "Big Data" exploitation.
Caroline Chung, MD, MSc, FRCPC, CIP, Vice President, Chief Data Officer, Director of Data Science Development & Implementation, Institute for Data Science in Oncology, MD Anderson Cancer Center
VP & Chief Data Officer
MD Anderson Cancer Center
Dr. Chung is Vice President and Chief Data Office and Director of Data Science Development and Implementation of the Institute for Data Science in Oncology at MD Anderson Cancer Center. She is a clinician-scientist, and associate professor in Radiation Oncology and Diagnostic Imaging with a clinical practice focused on CNS malignancies and a computational imaging lab focused on quantitative imaging and modeling to detect and characterize tumors and toxicities of treatment to enable personalized cancer treatment. Motivated by challenges observed in her own clinical and research pursuits, Dr. Chung has developed and leads institutional efforts to enable quantitative measurements for clinically impactful utilization and interpretation of data through a collaborative team science approach, including the Tumor Measurement Initiative (TMI) at MD Anderson. Internationally, Dr. Chung leads several multidisciplinary efforts to improve the generation and utilization of high-quality, quantitative data to drive research and impact clinical practice, including her role as Vice Chair of the Radiological Society of North America (RSNA) Quantitative Imaging Biomarker Alliance (QIBA), Co-Chair of the Quantitative Imaging for Assessment of Response in Oncology Committee of the International Commission on Radiation Units and Measurements (ICRU) and National Academies of Sciences, Engineering, and Medicine (NASEM)-appointed committee addressing Foundational Research Gaps and Future Directions for Digital Twins. Beyond her clinical, research, and administrative roles, Dr. Chung enjoys serving as an active educator and mentor with a passion to support the growth of diversity, equity, and inclusion in STEM, including her role as Chair of Women in Cancer ( http://www.womenincancer.org/ ), a not-for-profit organization that is committed to advancing cancer care by encouraging the growth, leadership, and connectivity of current and future oncologists, trainees and medical researchers.
Brian Claus, Executive Director, RBI&T Molecular Design Technologies, Bristol Myers Squibb Co.
Executive Director, RBI&T Molecular Design Technologies
Bristol Myers Squibb Co
Christopher Colucci, Vice President, IT & Clinical, Clinical & Commercial & Enterprise Systems, Insmed, Inc.
VP IT
Insmed Inc
Chris Colucci is Vice President of IT at Insmed, a global biopharmaceutical company headquartered in Bridgewater, NJ. He leads technology strategy and delivery across Research, Clinical, and Commercial functions, as well as Emerging Technologies, the organization's hub for enterprise AI innovation. Chris has helped drive Insmed's AI transformation by leading the development and launch of the company's enterprise AI platform and an AI governance framework designed to support responsible, scalable innovation across the organization. An advocate for responsible AI adoption in the life sciences, Chris focuses on building the people, processes, and platforms that make technology a business differentiator. He brings a practitioner's perspective to enterprise AI strategy, IT governance, and digital transformation in biopharma.
Jiayi Cox, PhD, Data Scientist II, Novartis Institutes for BioMedical Research (NIBR)
Data Scientist II
Novartis Institutes for BioMedical Research (NIBR)
Jiayi Cox is a data scientist who delivers deep learning solutions on biologics at Novartis Institutes for BioMedical Research (NIBR). Her research interests include using graph neural network to model protein interactions and using language models to find protein binding site. Jiayi is experienced in several fields of studies including human genetics, molecular biology, and NGS data analysis. Prior to NIBR, she helped prioritize biomarkers nomination as a machine-learning scientist at a Boston-based pharmaceutical start-up. She obtained her PhD degree from Boston University on computational biology.
Cindy Crowninshield, Executive Event Director, Cambridge Healthtech Institute
Executive Event Director
Cambridge Healthtech Institute
Cindy Crowninshield, RDN, LDN, HHC is Executive Event Director of the Bio-IT World Conference & Expo, where she leads programming at the intersection of AI, data, informatics, and digital transformation across life sciences, biotech, pharma, and healthcare. Since joining Cambridge Innovation Institute in 2005, Cindy has played a central role in the evolution of Bio-IT World into a premier global event focused on the technologies, AI-driven innovations, and data strategies accelerating biomedical research, drug discovery, and precision medicine. She has led the conference since 2007, driving content spanning generative AI, multimodal data, bioinformatics, precision medicine, intelligent lab automation, knowledge graphs, and enterprise-scale scientific infrastructure. Her work focuses on identifying emerging technologies and operational trends shaping modern R&D while connecting cross-disciplinary leaders across science, technology, healthcare, and enterprise innovation. In addition to conference leadership, Cindy hosts and develops the Inside Bio-IT interview series, spotlighting innovators advancing AI, computational biology, precision medicine, and next-generation R&D infrastructure. She actively connects with researchers, startups, and industry leaders interested in showcasing breakthrough research, operational case studies, and emerging technologies through Bio-IT programming, interviews, and collaborative industry initiatives. Cindy is also a licensed registered dietitian, author, adjunct instructor, and one of the founding members of the Women in Bio Greater Boston chapter.
Alireza Daneshvar, Co-Founder & CEO, Pioneera Biosciences
Co-Founder & CEO
Pioneera Biosciences
Dr. Alireza Daneshvar, PharmD, MPH, IFIA-Inv, is a Forbes 30 Under 30 honoree, award-winning bio-pharmaceutical scientist and Chemistry Olympiad gold medalist dedicated to the life sciences, healthcare and biopharma sectors. With a background in pharmacology, biotechnology, medicinal chemistry, nanotechnology and drug design, he has built experience across research, project management and advisory roles. He is the Founder and CEO of Pioneera Biosciences, developing AI-designed immunotherapies. Recognized with patents and awards.
Vinod Das, Associate Director, Pharma R&D, Drug Innovation and AI Enablement, Bayer Pharmaceuticals
Associate Director
Bayer Corporation
Vinod Das is a leading techno-functional expert with over 25+ years of experience in Pharmaceutical Research & Development IT. He is currently responsible for Artificial Intelligence enablement at Bayer Pharmaceuticals, he drives the integration of Generative AI and Language Models (LLMs) to accelerate drug discovery and clinical development. Vinod's strategic leadership in AI enablement has set new standards in pharma-tech innovation, earning him recognition as a key influencer in the industry. He actively collaborates with top academic institutions, and AI vendors to foster cutting-edge research and sustainable AI innovation. Vinod’s work bridges the gap between advanced technology and real-world applications, making him a thought leader in AI-driven healthcare outcomes.
Helena Deus, PhD, Lead for Semantic Data Products, Bristol Myers Squibb Co.
Director, Research IT
Bristol Myers Squibb
Lena is Lead for Semantic Data Products at Bristol Myers Squibb. She is a data science and bioinformatics expert with extensive experience in delivering value to her clients through effective data governance, data analysis, and predictive AI, particularly within the R&D and Healthcare sectors. With proficiency in FAIR principles, she actively contributes to pre-competitive consortia such as the Pistoia Alliance, ensuring that her clients are equipped with awareness of industry standards. Lena holds a PhD in Bioinformatics from Universidade Nova de Lisboa (2011) and an MS in Biology from Universidade de Lisboa (2004). She has received 9 awards, including the Elsevier Silver Coin and the NASA Space Apps Challenge winner. Lena has authored over 50 peer-reviewed publications in healthcare and life sciences, accumulating more than 1000 citations. Additionally, she has a patent to her name and has delivered 5 keynote addresses.
Sahil Dhingra, Senior Manager, Product Management, Regeneron Pharmaceuticals
Product Lead
Regeneron Pharmaceuticals, Inc.
Sahil Dhingra is a Product Lead at Regeneron with 17 years of experience turning complex clinical data into trusted, actionable insights. His work spans clinical data platforms, risk-based monitoring, and external data integration, with a consistent focus on helping clinical teams make better decisions, faster. With a background in data science and GxP-regulated environments, Sahil has built AI-powered products that bring unstructured data into the decision process. He believes the real potential of AI starts with trusted data and focuses on building the foundations that make it possible.
Shagun Doshi, Senior Business Analyst, Bristol Myers Squibb Co.
Senior Business Analyst, DAP
Bristol Myers Squibb Co
Shagun Doshi is a Senior Business Analyst for Translational Medicine & Semantic Data Products at Bristol Myers Squibb, within Research and Business IT. She works on the Biomarker Data Product, which consolidates closed-study biomarker data into a single table, making it easier for research teams to find and reuse across studies. At Bio-IT World, she will present how the team brought this data together and how AI tools can make closed-study biomarker data more accessible for research use.
Greg Dungca, Senior Data Engineer, Genentech, Inc.
Senior Data Engineer
Genentech
Greg Dungca is a Senior Data Engineer at Genentech, developing data and AI capabilities for drug discovery. He has nearly a decade of software engineering experience building scalable life sciences data platforms and backend systems, with previous engineering roles at Freenome and Syapse. His work focuses on making complex scientific data reliable, accessible, and AI-ready. He holds a Bachelor of Applied Science in Industrial Engineering from the University of Toronto.
Chris Dwan, Fractional CIO, Triveni Bio
Independent Consultant
Dwan, LLC
Chris Dwan is a technologist who has spent a quarter century working in the life sciences with a focus on genomics. He was the first employee at BioTeam, built the IT and data infrastructure for the NY Genome Center, led Research Computing and IT at the Broad Institute, and served as the SVP of Production Bioinformatics at Sema4. Chris is currently fractional CIO of Triveni Bio and serves on the advisory boards of several startups.
Felix Francis, PhD, Associate Director, Data, Data Science and Artificial Intelligence, Immunology, Johnson & Johnson Innovative Medicine
Associate Director
Johnson & Johnson
Felix Francis is an Associate Director in DDSAI at Johnson & Johnson, supporting Immunology Discovery and Translational Sciences. He brings more than 14 years of experience across pharma, biotech, and academia spanning bioinformatics, scientific data, advanced analytics, and AI-enabled R&D. Prior to J&J, Felix held leadership roles at Takeda and Abcam, leading and contributing to initiatives in R&D data integration, semantic data models, bioinformatics, and antibody discovery. He holds a PhD in Bioinformatics & Systems Biology, and his current focus is on building governed, AI-ready scientific data products and platforms that connect data, knowledge, analytics, and AI to accelerate drug discovery and translational research.
Giorgio Gaglia, PhD, Head of Systems & Disease Biology, Target & Disease & Systems Biology, Sanofi Group
Sr Distinguished Scientist, Head of Systems & Disease Biology
Sanofi R&D
Giorgio has an interdisciplinary background in pure mathematics (MMaths, Oxford University) and a systems biology PhD (Harvard Medical School). Giorgio’s academic research centered on applying quantitative biology approaches to (1) temporal dynamics of protein multimerization and aggregation in single cells (p53 and HSF1) and (2) the spatial organization of tumor microenvironment and its impact on tumor phenotypes. Giorgio joined Sanofi in January 2022 and he is currently the Systems & Disease Biology cluster head in the Target, Disease, and Systems Biology function. The group’s work leverages computational methods and omics technologies to fuel a wide range of projects around novel target identification, understanding drugs mechanism of action and patient heterogeneity—in tight collaboration with all of Sanofi’s R&D Therapeutic Areas.
Anand Ganesan, Product Lead, GD-IT, Regeneron Pharmaceuticals, Inc.
Product Lead, GD-IT
Regeneron Pharmaceuticals
A Product Leader with a demonstrated history of delivering clinical IT transformations for pharma, biotech/CROs with a Wharton Management Development Program, Kellogg Product Strategy and Stanford Advanced Program Management from Stanford University. He is a big believer in product innovation and leads large teams in product development using SAFe Agile methodologies. He is an ex-IQVIA/ex-Medidata with 20+ years in clinical IT. Anand is a tech savvy leader with interests in AI, big data, blockchain and use them to address the challenges faced by the life sciences industry. Anand loves participating in hackathons and social innovation activities in the life sciences/ healthcare space. More recently Anand was a semi- finalist in 'HITLAB Breakthrough One' Challenge featuring EZTrialFinderâ„¢, a Gen AI driven innovative solution enable patients find clinical trials from their mobile phone.
Manasi Ghogare, Senior Technology Product Manager, Digital Health, Takeda Pharmaceutical Co., Ltd.
Sr Tech Product Mgr
Takeda Pharmaceutical Co Ltd
Manasi Ghogare is a product leader in Digital Health where she has led cross functional teams to design and deliver digital solutions that sit at the intersection of patient needs, clinical workflows, and responsible AI. With a background spanning product management, data driven decision making, and technology governance, Manasi focuses on turning complex problems into pragmatic, human centered workflows. She is particularly passionate about helping product teams move beyond “add AI” requests to build safe, useful, and adoptable AI enabled products.
Jonathan B. Gilbert, PhD, Senior Director, Ecosystem Growth and Contributor Partnerships, Eli Lilly and Company
Sr. Director - Ecosystem Growth and Contributor Partnerships
Eli Lilly and Company
Jonathan Gilbert leads the growth of the Lilly TuneLab Ecosystem worldwide. Jonathan received his PhD from MIT in Chemical Engineering and has spent his last decade plus in biotech at multiple companies ranging from the Seed stage to early clinical public companies. Immediately prior to Lilly, Jonathan lead Corporate Development and Strategy at Entact Bio.
Oscar Gil-Gonzalo, Director, Emerging Technology Intelligence, IT, AstraZeneca
Dir Emerging Technology Intelligence
AstraZeneca
Oscar Gil is Director, Emerging Tech Intelligence at AstraZeneca, working at the intersection of emerging technology, business strategy, and external innovation. He focuses on anticipating how new technology developments could shape the future of biopharma and translating those signals into actionable opportunities for the organization. His work combines emerging technology intelligence with business engagement and ecosystem partnerships, connecting AstraZeneca with technology leaders, startups, universities, research institutions, and other innovators. His areas of interest include the evolution of artificial intelligence beyond today’s generative AI, quantum technologies, and the broader convergence of technologies that could transform how life sciences organizations discover, develop, and deliver medicines.
Rishi R. Gupta, PhD, Director, Data Science, Novartis Institutes for Biomedical Research, Inc.
Director, CADD/Data Science
Novartis
Rishi has over 18 years of experience in Pharma in various capacities. In his current role as a Director within the CADD/GDC group at Biomedical Research, Novartis at Cambridge, MA, he is leading several efforts in applying cheminformatics, data science, AI/ML and molecular modeling methods for advancing drug discovery and development. Prior to Novartis, Rishi was at AbbVie, where he led the Data Science and Informatics group. At AbbVie, he conceptualized and developed a web-based infrastructure to expose suite of Cheminformatics tools called AIDEAS. He developed and deployed machine-learning models for a variety of bioassay data including ADMET endpoints. In his extended role within Competitive Intelligence (CI), Rishi developed web based visual-analytic analytic frameworks for exposing genomics data, clinical Trials data and a variety of other CI related landscapes. Prior to AbbVie, Rishi was at Pfizer Global Research and Development as a Computational Chemist where he had broad set of responsibilities ranging from developing ADMET in-silico models, novel scoring methods such as confidence metrics for in-silico models. He also supported the Anti-Bacterial research organization. Rishi earned his PhD. from University of Connecticut and MS at University of Massachusetts, Amherst.
Benjamin M. Gyori, Research Fellow Therapeutic Science, Systems Biology, Harvard Medical School
Research Fellow Therapeutic Science
Harvard Medical School
Celine Han, Senior Scientist & Computational Biologist, Bristol Myers Squibb Co.
Senior Scientist & Computational Biologist
Bristol Myers Squibb
Celine Han is a computational biologist and senior scientist in Translational Bioinformatics at Bristol Myers Squibb (BMS). Her focus of research is to advance oncology clinical trial programs and to influence development strategies by applying cutting-edge bioinformatic analyses on clinical trials and real-world data. Her work involves driving complex collaborations and communications with various partners for biomarker discovery and patient stratification. Prior to joining BMS, she finished her postdoctoral training at Harvard Medical School, Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard. She studied the resistance to hormone therapy for patient stratification in metastatic prostate cancer. She completed her Ph.D. training in Bioinformatics and Genomics at Pennsylvania State University studying the epigenetics and transcriptional regulation in erythropoiesis. Outside of research, she is passionate about science communication, mentoring, teaching, and being a lifelong learner.
YiXing Han, PhD, Staff Scientist, NIH NHGRI
Staff Scientist
NIH NHGRI
Yixing Han, Ph.D., is an interdisciplinary scientist specializing in computational human genetics, genomics, and precision health. Her work integrates statistical genetics, multi-omics, clinical genomics, and biomedical data science to investigate how genetic variation and biological context shape human health. She also leads computational research-program development, multidisciplinary studies, and trainee mentorship.
Eleanor A. Howe, PhD, Founder & CEO, Diamond Age Data Science
Founder & CEO
Diamond Age Data Science
Eleanor Howe is the CEO of Diamond Age Data Science. Before founding Diamond Age in 2017, Eleanor spent nearly two decades in bioinformatics — first building open-source tools, then moving into drug discovery at the Broad Institute. Her firm has now worked inside more than 100 life science companies — from two-person startups to top-10 pharma — which gives her an unusually broad view of what's actually working in the field right now.
Julie Huxley-Jones, Vice President, Research, Pre-Clinical, Manufacturing and Supply Chain Data Technology, Vertex Pharmaceuticals
Vice President, Research, Pre-Clinical, Manufacturing and Supply Chain Data Technology
Vertex Pharmaceuticals
Julie Huxley-Jones is a seasoned leader in the biopharmaceutical industry, known for her expertise at the intersection of science, technology, and digital transformation. With a background in scientific research and a passion for innovation, she has spent over 18 years driving digital strategies across R&D functions in major pharmaceutical companies. In her current role as Vice President of Research, Pre-Clinical, Manufacturing and Supply technology at Vertex Pharmaceuticals, Julie champions the use of cutting-edge technologies to transform how medicines are discovered, developed and distributed to patients in need around the world.
Bowen Jing, Head, Machine Learning, Divergence Labs
Head
Divergence Labs
Bowen is the Head of Machine Learning at Divergence Labs, a biotechnology research lab building repeatable methods to discover high-value therapeutics. These activities span fundamental research in AI for drug discovery, high-throughput experiments, and multiple programs in ophthalmology and I&I. Bowen received his PhD in Computer Science from MIT, where he pioneered generative models for drug discovery, molecular simulation, and protein design.
Duncan Johnstone, Senior Director, Data, Automation & Predictive Sciences, GSK
Senior Director - Data, Automation & Predictive Sciences
GSK
Duncan is leading GSK's Lab-in-an-Automated-Loop project within the R&D Technologies organization. Prior to this, he led data science for target discovery and human genetics and genomics.
Vivek Kaimal, PhD, Executive Director, Head of Genomics, Bioinformatics & Data Science, Translational Sciences, Allogene Therapeutics
Exec Dir, Head of Genomics & Bioinformatics
Allogene Therapeutics
Vivek Kaimal is the Executive Director, Translational Sciences, and Head of Genomics, Bioinformatics and Data Science of Allogene. Vivek built the company’s genomics and bioinformatics function from its inception and leads the multi-omic and translational analytics supporting Allogene’s AlloCAR T programs in oncology and autoimmune disease, spanning single-cell and immune-repertoire sequencing, circulating tumor DNA, and translational biomarker data. At Allogene he has established reproducible analytical infrastructure across the company’s clinical programs, overseen external research collaborations, and led the integration of large language models and AI agents into translational analysis workflows, including the independent verification framework presented here. Prior to joining Allogene in 2021, Vivek built and led the bioinformatics and computational biology functions at Rheos Medicines, and held senior bioinformatics roles at AbbVie and Regulus Therapeutics. His work has been published in Nature, Cancer Discovery, the Journal of Clinical Investigation, Science Translational Medicine, and Molecular Therapy. He holds a Ph.D. in Biomedical Engineering and Bioinformatics from the University of Cincinnati.
Petrina Kamya, PhD, Global Head of AI Platforms and Vice President, Insilico Medicine; President, Insilico Medicine Canada
Global Head of AI Platforms, VP
Insilico Medicine, Canada
Petrina Kamya, PhD, is the Head of AI Platforms and President of Insilico Medicine, Canada an end-to-end artificial intelligence-driven drug discovery company. Before joining Insilico, Dr. Kamya spent eight years in various roles at Chemical Computing Group that involved scientific and business-related aspects of preclinical drug discovery. In addition to establishing the corporate strategy for the sales and business development of molecular modeling software for academia, she also played an active role as an application scientist working on real-world discovery projects and finally in a senior role in strategy and business development for pharma and biotech companies. Following her time at CCG, Petrina moved to Certara as a Market Access Manager, where she learned first-hand the challenges of getting drugs to market. Petrina has been with Insilico Medicine since August 2020. She holds a PhD in Chemistry (specializing in computational chemistry) from Concordia University.
Gurpreet Kanwar, Senior Manager Programs, Portfolio Delivery Group, NAV CANADA
Senior Manager, Programs
NAV CANADA
Gurpreet Kanwar is a senior leader with over 28 years of experience in IT, project planning, and program delivery, including more than 14 years in project and program management. At NAV CANADA, he has been instrumental in establishing and maturing the PMO, standardizing methodologies, and leading the Integrated Workstation Program (IWP) across 36 towers nationwide, including Canada’s busiest airports. Gurpreet has a proven record of delivering complex digital transformation initiatives, driving governance improvements, and mentoring project leaders under demanding conditions. Known for his collaborative approach, he works closely with executives, stakeholders, and vendors to align strategy and delivery. Gurpreet holds an MBA from Edinburgh Business School and has presented at multiple project management and technology conferences.
Kiran Kodali, MBA, Head of R&D Data Governance, BeiGene
Head of R&D Data Governance
BeOne Medicines
Kiran Kodali is Head of R&D Data Governance at BeiGene. Previously, he lead the R&D Data Strategy and Governance at Sanofi (Pharma / Life Sciences). Kiran has had the opportunity to work across industries - including investment banking, US military and business aviation - with a focus on enabling business objectives from a data and digital standpoint. He has expertise in building and scaling capabilities across functions, that allow monetization on the data generated/acquired, to support decision making and improve business outcomes along the value chain.
Adam Kraut, Director, Research Informatics and Data Architecture, Metaphore Bio
Director Research Informatics
Metaphore
Dynamic technical leader, pioneering at the intersection of AI, cloud architecture, and life sciences. 15+ years leading the development of sophisticated cloud-based infrastructures that serve as the backbone for critical data analytics in precision medicine and biotech. Shaped by the discipline of Brazilian jiu-jitsu, passionate about performance, adaptability, and strategic foresight.
Robert Krueger, PhD, Assistant Professor, New York University
Assistant Professor
New York University
Robert Krueger is an assistant professor at New York University (NYU). Previously, he was a postdoctoral research fellow and subgroup leader at VCG Harvard, School of Engineering and Applied Sciences at Harvard University, and a senior research scientist at the Laboratory of Systems Pharmacology, Harvard Medical School. Dr. Krueger received his MS in Computer Science and Media at the Stuttgart Media University in 2012 and his Ph.D. degree (Dr. rer. nat.) in Computer Science at the Institute for Visualization and Interactive Systems, University of Stuttgart in 2017. Krueger's research interests lie in the field of data visualization and visual analytics for on spatial and spatially-referenced multivariate data with a focus on biomedical visualization.
MengWei Kuo, PhD, Executive Director, CMC & AI Enabled Development, HanchorBio, Inc.
Exec Dir CMC & AI Enabled Dev
HanchorBio Inc
Mengwei Kuo is Executive Director of CMC & AI-enabled Development at HanchorBio, a global clinical-stage biotechnology company developing next-generation immunotherapies through its proprietary Fc-based Designer Biologics (FBDBâ„¢) platform. She also leads cross-functional AI-enabled development initiatives. Her experience spans biologics process development, analytical strategy, formulation, technology transfer, regulatory development, and complex biologic modalities. Her current work focuses on the interface between computational molecular design, AI-enabled drug development, and downstream biologics development, especially how public and internal evidence can be calibrated, translated into explicit molecule-selection criteria, and connected to experimental validation. She is particularly interested in building reusable scientific decision systems for Fc engineering, developability, and CMC development.
Kejie Li, PhD, Vice President & Head of Data Science, Triveni Bio
VP
Triveni Bio Inc
Kejie Li, PhD, is Vice President and Head of Data Science at Triveni Bio, where he leads computational biology, data infrastructure, and AI/ML initiatives supporting the discovery and development of precision medicines for inflammatory and immune diseases. With over 15 years of experience spanning biotech, pharma, and academia, his work bridges human genetics, omics data analysis, and applied machine learning to accelerate drug discovery. Prior to Triveni Bio, Kejie held computational biology and data science roles at Biogen and an Atlas Venture-backed biotech startup. He completed a postdoctoral fellowship in the Chemical Biology Program at the Broad Institute of MIT and Harvard, earned his PhD in Computational Biology from Purdue University.
Michael Liebman, PhD, Managing Director, IPQ Analytics, LLC
Managing Dir & Co Founder
IPQ Analytics LLC
Michael N. Liebman, PhD (theoretical chemistry and protein crystallography) is Managing Director of IPQ Analytics, LLC and CSO of United Cancer Centers after serving as Executive Director of the Chan Soon-Shiong Institute for Molecular Medicine. He is Adjunct Professor of Pharmacology and Physiology, Drexel College of Medicine and Adjunct Professor of Drug Discovery, Wenzhou Medical University and Fudan University. He serves on the Advisory Board for the Center of Biomedical and Health Research, University of Massachusetts (Lowell). Previously, he was Director, Computational Biology and Biomedical Informatics, University of Pennsylvania Cancer Center. He served as Global Head of Computational Genomics, Roche. He serves on the Board of the Nathaniel Adamczyk Foundation in Pediatric ARDS. Michael chairs Translational Medicine for the PhRMA Foundation and serves on the IUPAC Division on Human Health. His research focuses on computational models of disease that stress complexities of real-world patients and real-world clinical practice utilizing systems-based approaches for representation and analysis for pharma and healthcare. Current application areas include: multiple sclerosis, heart failure, and a focus on women’s health: triple negative breast cancer, hypertension and hypertensive disorders of pregnancy, infant-maternal morbidity and mortality, perimenopause-menopause transition with an emphasis on underserved populations and health disparities.
Ana Maria Lopez, MD, MPH, MACP, Professor of Medical Oncology and Integrative Medicine and Nutritional Sciences, Thomas Jefferson University
Professor of Medical Oncology and Integrative Medicine and Nutritional Sciences
Thomas Jefferson University
Dr. Lopez is an experienced researcher in the field of oncology, telemedicine, and patient-centered care. Dr. Lopez, a graduate of Bryn Mawr College (A.B. Philosophy) and Jefferson Medical College of Thomas Jefferson University (M.D.), is dedicated to translational research that improves access to care and the reduction of health disparities. She completed residency training in Internal Medicine, served as a Chief Resident and completed fellowships in General Internal Medicine and Medical Oncology at the University of Arizona. As a Fellow in Medical Oncology, Dr. Lopez was awarded a Cancer Prevention and Etiology Fellowship from the National Institute of Health. Concurrent with her subspecialty training, she completed a MPH at the University of Arizona and was awarded the Epidemiology Award ($10,000) for outstanding accomplishments. She then joined the University of Arizona College of Medicine faculty and also became the Associate Dean for Outreach and Multicultural Affairs. In 1997, she was designated as the founding Medical Director of the Arizona Telemedicine Program. With a passion for addressing issues on access to care, Dr. Lopez has embedded this priority in a majority of her studies. Studies have ranged from health research at the biological molecular level to the broader systematic health delivery level, all of which contribute to establishing optimal health care for individuals and communities. Her most recent work has focused on the promotion of patient-reported outcomes, which are intended to reflect an individual’s perspective on and participation in his or her health. This work primarily focuses on developing patient-centered technologies, which range from a patient symptom self-management program, to a patient portal to monitor health and communicate with a care team, and a screening and diagnostic decision-making tool to promote the adoption of screening recommendations. These projects have focused on serving disease-specific populations, with the intention of serving a larger population in the future. Dr. Lopez’s research, outreach, and her realization of her beliefs have been acknowledged on numerous occasions, with recent recognitions including Women of the Year by the Hispanic Professional Action Committee (2010), Best Doctors in America (1998-2010), America’s Top Oncologists (2007 and 2008), and the Peter W. Likins Inclusive Excellence Award (2009).
Aviv Madar, PhD, Director, Data Scientist, Valo Health
Founder and Principle Engineer
Invariant Systems LLC
Aviv Madar, PhD, builds agentic AI systems for statistical genetics and computational biology, with an emphasis on analyses that cite the convention behind every cutoff they apply and surface their own uncertainty rather than resolving it quietly. He spent five years at Valo Health as Director of Data Science, leading causal inference and then target validation. There he built the genetics-based causal inference function, covering Mendelian randomization, colocalization, and multi-omic polygenic scoring, and the target validation playbooks used across discovery programs. Before Valo he led clinical genetics for Translational Medicine at the Novartis Institutes for BioMedical Research, owning non-oncology genetic profiling across Phase I-III trials and representing Novartis in FinnGen and the COVID-19 Host Genetics Initiative. He earned his PhD in genomics and systems biology at New York University and trained in regulatory genomics at NYU and Cornell. His work on gene regulatory networks appeared in Cell, and his publications have been cited more than 6,500 times.
Saurav Mahanti, Vice President, Information Technology, Allogene Therapeutics
Vice President, Information Technology
Allogene Therapuetics
Saurav Mahanti is the Vice President, Information Technology, of Allogene Therapeutics. He leads the company's IT organization, including infrastructure, enterprise applications, and security and compliance, supporting a clinical-stage biotechnology company operating in a regulated environment. His team supports the systems used across clinical development and manufacturing for Allogene's AlloCAR Tâ„¢ programs. At Allogene, he has established the company's data governance and data platform architecture and has led the secure adoption of enterprise AI tools across the company. Saurav has more than two decades of experience delivering data, analytics, and business solutions across the biopharmaceutical industry, spanning clinical development, manufacturing operations, commercial, and finance. Prior to joining Allogene in 2020, he was Data Engineering Lead at Facebook, where he built the data architecture supporting the company's elections integrity and research work. He also contributed to the Facebook Privacy-Protected Full URLs Data Set, released to academic researchers through Harvard Dataverse in collaboration with Social Science One. Before that, he spent more than 15 years at Amgen, progressing from systems analyst to Director of Data and Analytics for Process Development and Operations, where he was responsible for technical delivery of the enterprise data warehouse platform and led the big data strategy and Enterprise Data Lake. He holds a Bachelor of Engineering in Electronics and Telecommunications Engineering from University College of Engineering, Burla.
Shipra Malhotra, PhD, Senior Scientist, Biologics, Computational Biology and Machine Learning, Takeda
Senior Scientist
Takeda Pharmaceuticals Company
PhD in Computational Biology from the University of Kansas, with a focus on data collection, analysis, and interpretation, as well as the development and implementation of cutting-edge in silico tools for drug discovery and design. Currently, as a Senior Scientist at Takeda Pharmaceuticals, I spearhead the design, characterization, and optimization of therapeutic candidate drugs through computational analysis of protein sequence and structure, computational protein design, and engineering. I'm deeply engaged in pioneering AI-driven approaches to generate human-like proteins, particularly in the domain of antibody-based therapeutics.
Steve Marshall, Founder & Principal Consultant, Seapoint Consulting
Principal Consultant
Seapoint Consulting
Lab scientist turned computational biologist and data leader, with 25+ years at Novartis, Flagship Pioneering and early-stage biotechs. I help research teams make good use of data, cloud and AI, and I enjoy building relationships and communities that make the work more meaningful. More recently, I’m building a coaching practice and completing UC Davis’s Coaching for Life and Work Certificate Program.
Iona McCall, Account Manager, bPrescient
Account Manager
bPrescient
Iona McCall combines a background in biology, computer science, and bioinformatics with cutting-edge technology and data-driven insights to advance biotechnology and pharmaceutical research, advance healthcare, and improve patient outcomes. She works with a team of more than 200 experts at bPrescient, a full-service scientific and technology consultancy that provides a unique combination of advantages to accelerate and de-risk the drug R&D process. Together, they speed up drug research and clinical pipelines by solving the most intractable R&D problems facing pharmaceutical and biotech organizations.
Sean McClain, Founder & CEO, Absci Corp.
Founder & CEO
Absci Corp
Sean McClain is the founder and CEO of Absci, a clinical-stage biopharmaceutical company working at the intersection of generative AI, experimental biology and drug development. He founded Absci in 2011 at age 22 and has led its evolution from a synthetic biology startup into a publicly traded company building an integrated system for designing and advancing new biologic medicines. McClain’s vision extends beyond using AI to make traditional drug discovery faster. He believes generative AI can give scientists new tools to design medicines around biological outcomes that were previously difficult to pursue, including emerging approaches to regenerative health. Through Absci’s internal pipeline and drug-creation technology, he is working to test whether that vision can move from computational design and laboratory biology into human medicine. ABS-201, now in a Phase 1/2a trial, is among the first generative-AI-designed antibodies to reach the clinic.
Ravi Mehrotra, MD, PhD, Chief Medical Officer, Open Health Systems Laboratory (OHSL)
Chief Medical Officer
Open Health Systems Laboratory (OHSL)
Ravi Mehrotra, MD, PhD, is a physician-scientist and cancer researcher with extensive international experience in precision oncology, cancer prevention, molecular pathology, clinical research, and public health. As Chief Medical Officer at Open Health Systems Laboratory (OHSL), he focuses on integrating emerging technologies, including informatics, natural language processing, and data analytics, into cancer research and clinical applications. Dr. Mehrotra previously served as CEO of the India Cancer Research Consortium and Director of the ICMR-National Institute of Cancer Prevention and Research, where he led national cancer research initiatives, screening programs, and clinical capacity-building efforts. His experience also includes roles with the CDC Foundation, Emory University, and the Fed Hutch, with expertise spanning clinical trials, medical device evaluation, regulatory affairs, and global cancer control. He has authored more than 350 scientific publications, including research articles, book chapters, and books, and has received advanced training at Johns Hopkins University and the University of Pennsylvania.
Adam Mendez, Senior Director, Data & Cloud Platforms, Flagship Pioneering
Senior Director, Data & Cloud Platforms
Flagship Pioneering
I design and lead cloud and data platforms that help scientists and biotech teams move faster, automate more, and turn complex research into scalable, repeatable workflows. Across my career, I’ve focused on building the kind of infrastructure that quietly powers everything else: secure AWS foundations, high-throughput pipelines, unified data layers, and ML platforms that scientists can actually use. I enjoy operating at the intersection of engineering and biology, where the right architecture can open the door to discoveries that weren’t possible before. Today at Flagship Pioneering, I’m building the core cloud environment that supports a growing portfolio of early-stage biotech companies. This includes the AWS Organization structure, networking, governance, and automation patterns that allow teams to scale without friction. I also architected the CryoEM data pipeline capable of streaming more than 50 TB/day into S3, enabling near–real-time analysis and automated validation for structure determination and AI-driven research. Before this, I led Cloud and Data at Resilience, where I built global teams and created the company’s data operating model—from instrument connectivity and data ingestion, to a full data mesh, to an internal LLM platform. I’m proud of the impact that work had: connecting hundreds of instruments across the world, improving how scientists accessed information, and dramatically reducing cloud spend while improving reliability. Earlier roles at Vertex, Miltenyi/Qiagen, and the Broad Institute gave me deep experience in distributed systems, bioinformatics, and large-scale data engineering. They also shaped my belief that the best platforms are the ones that make complex science feel simple. I’m motivated by building systems that let people do their best work: infrastructure that scales, data that can be trusted, and tools that make advanced analytics and machine learning part of everyday research—not an afterthought.
Helen Merianos, PhD, CEO, PeloMer
Chief Executive Officer
PeloMer
Helen is Chief Executive Officer of PeloMer. PeloMer helps life sciences companies, investors, and executive leadership teams make better strategic decisions, optimize portfolios, accelerate innovation, and harness artificial intelligence to create measurable business value. She was formally Global Head of R&D Strategy and Portfolio Management at Sanofi, responsible for managing Sanofi’s innovative portfolio across R&D Pharma and Vaccines. Helen and her team lead the end-to-end strategic portfolio business transformation, which enables portfolio trade-off decisions and improves strategic planning at a corporate level. Helen joined Sanofi in 2021 as Head of Portfolio Decision Resources to lead a business transformation in portfolio decision making for R&D. In June 2022, she was promoted to Head of R&D Portfolio Strategy where she has pioneered the use of AI to drive portfolio strategy and co-developed an AI powered decision intelligence tool for R&D with Ailylabs. Prior to joining Sanofi, Helen held positions of increasing responsibility at GSK for nearly 15 years leading teams working on commercial insights and valuation assessment, portfolio strategy, investment and prioritization, and clinical development and commercialization strategy. Before working in healthcare, Helen started her career at McKinsey & Co. Helen holds a PhD in Biophysical Chemistry from Yale University.
Martina Miteva, Director, Strategic Digital Initiatives, Research & Early Development IT, Bristol Myers Squibb Co.
Dir Strategic Digital Initiatives
Bristol Myers Squibb Co
Martina Miteva is a Director, Cross-Functional Business Partnering in Research IT at BMS. She is passionate about delivering impactful digital change to her research colleagues.
Michael Montgomery, MD, Co-Founder and CMO, Tidewave Bio
Co-Founder and CMO
Tidewave Bio
Michael Montgomery, MD is Co-Founder and CEO of Stable Solutions, LLC a healthcare and neural net consultancy (If it isn’t stable; it’s not a solution). Dr. Montgomery is Board certified in Internal Medicine. He has over 23 years experience as a Cell Biologist working in the field of Developmental Biology at Washington University in St. Louis, Cornell Medical College, and Temple University Medical School. He was an Assistant Professor in the department of Anatomy and Cell Biology at Temple University School of Medicine. Dr. Montgomery has been a leader in Medical Development at Centocor, Johnson & Johnson and Incyte for two decades producing multiple successful projects including the development of QUEST, an award winning process automation system; ANUBIS, a system for prioritizing development opportunities for new and approved products; and UTOPIA, a project to establish processes for reviewing and running clinical trials in Medical Affairs. At J&J he was a co-founder and Leader of the Proof-of-Concept Team which prioritized reviewed, funded, supported and disseminated information from all, novel Investigator Sponsored Trials exploring new treatments in over 110 diseases in 20 therapeutic areas. He led the Global Medical Affairs team at Incyte as Interim Head. Dr. Montgomery was accredited as a Certified Physician Investigator by the Association of Clinical Research Professionals and led high performance teams at Centocor, J&J, and Incyte. Dr. Montgomery was also Founding President of the Investigator Initiated and Sponsored Research Association (iisra, iisra.org) and is a lecturer on the subjects of process, IT in Pharma and IISR.
Arturo J. Morales, PhD, Vice President, Technology Enabled Science, CSL Behring
VP, Head of Technology Enabled Science
CSL Behring
With over 20 years of experience in data science and technology, Art is a passionate and visionary leader specializing in enabling data-driven domains, particularly in pharma and biotech. At XponentL, he oversees the development and delivery of innovative and scalable data and AI solutions for complex challenges in life sciences and other industries.? Art has successfully led high-performing teams across multiple business units and domains, creating and deploying data products that enhance research, clinical, operational, and business outcomes. His mission is to empower data-driven decision-making and innovation to improve human health and life.?
Douaa Mugahid, PhD, Data Officer, Hi-IMPAcTB Consortium, Harvard School of Public Health
Data Officer for Hi-IMPAcTB Consortium
Harvard School of Public Health
Douaa Mugahid is a systems biologist by training and currently a Research Scientist and faculty member at the Harvard TH Chan School of Public Health which she joined after the COVID19 pandemic revealed the importance of better digital infrastructure, more interdisciplinary research, and public-private partnerships for local and global pandemic preparedness. In her current role, she wears multiple hats, among which is serving as the Data Officer for a large NIH-funded consortium of international, interdisciplinary researchers focused on leveraging multi-modal data from multiple species to identifying principled therapeutic and diagnostic strategies for adults at risk of TB – the world’s deadliest infectious disease by number of lives claimed. She also manages a partnership with Siemens Healthineers focused on using digitally-connected diagnostics for public health monitoring and improving health system performance. She is a part-time Senior Consultant at the Brussels-based boutique consulting firm myEUconsulting, where she helps high-risk but promising early-stage Biotech/Techbio/Digital Health startups obtain EU funding.
Yanay Ofran, PhD, Founder, CEO, Biolojic Design Ltd.
Founder & CEO
Biolojic Design Ltd
Yanay Ofran is a computational biophysicist and a biotech entrepreneur. His scientific work uses computational approaches to understand, predict and engineer protein interactions. Yanay is the founder and CEO of Biolojic Design. Biolojic AI-guided platform designs multi-functional antibodies that maintains the developability, half-life, stability and safety of human antibodies. Yanay is also the co-founder of Ukko, a biotech company that uses computational tools and patient samples to design a novel treatment for food allergies. He also a co-founded Aulos Biosciences, which became the first company to treat cancer patients with a computationally designed antibody. Prof. Ofran headed the lab of systems biology and functional genomics at Bar Ilan University near Tel Aviv.
Michael Paull, PhD, Data Engineer, Global Device Develoment & Engineering, Takeda Pharmaceutical Co. Ltd.
Data Engineer
Takeda Pharmaceutical Co Ltd
Michael Paull, PhD, is a Data Engineer in Takeda's Global Device Development and Engineering organization, where he develops automation and AI solutions to support device development. Previously, he was Bioinformatics and IT Manager at GV20 Therapeutics, where he developed large-scale transcriptomics pipelines and managed cloud computing platforms. His interests include automation, cloud computing, and the practical application of artificial intelligence to real-world scientific challenges.
Angel Pizarro, Product Architect, Digital Biology, NVIDIA Corp.
Product Architect
NVIDIA Corp
Angel Pizarro is a Product Architect within the NVIDIA Digital Biology product team, focused on accelerated software and foundation models for genomics. He has over 25 years of experience in genomics and bioinformatics research, and research IT operations with a focus on enabling, scaling, and accelerating high-throughput genomics technologies.
Tom Plasterer, PhD, CEO & Co-Founder, Knowledge3
CEO & Founder
Knowledge3 LLC
Tom Plasterer, PhD, is the founder of Knowledge3 (K3), where he designs knowledge-first data systems that transform fragmented biomedical data into computable, explainable intelligence for research and development. His work focuses on structuring systems so that scientific questions directly drive data modeling, computation, and AI, enabling more transparent and reliable decision-making in translational medicine. With more than two decades of experience across industry and academia, Tom has led initiatives in bioinformatics, biomarker discovery, and data strategy at organizations including AstraZeneca, BG Medicine, and XponentL Data. He is an active contributor to the life sciences knowledge community and co-organizes the Health Care and Life Sciences symposium at the Knowledge Graph Conference.
Limeng Pu, PhD, Senior Computational Research Scientist, Computational Biology, St. Jude Children's Research Hospital
Sr Computational Research Scientist
St Jude Childrens Research Hospital
Limeng Pu, Senior Computational Research Scientist, Department of Computational Biology, St. Jude Children’s Research Hospital. His research focuses on machine learning for cancer genomics and the evaluation of AI agents for scientific discovery. His work includes CancerOmicsNet and DeepDrug3D, and he currently develops foundation models for DNA methylation and benchmarks for scientific discovery agents.
Yu Qiu, PhD, Executive Director, Biologics Design and Technology, AstraZeneca
Executive Director
AstraZeneca
Yu Qiu is currently Digital Biologics Advance Application Lead (Senior Principal Scientist) at Sanofi. He earned his PhD in Biochemistry in 2012, where he mainly used NMR to study protein structures and dynamics.Then he moved to St. Jude Children’s Research Hospital as a postdoc where he studied a Ubiquitin-like protein conjugation cascade in autophagy by biochemistry, enzymology, crystallography and EM. In 2017, Yu became a Senior Scientist in the Biologics Research department of Sanofi. At Sanofi, he solves structures of antibody-antigen complexes by crystallography and cryoEM and provides structure-based antibody engineering support to projects in multiple therapeutic areas. Since early last year, he has led a small group focusing on in silico antibody engineering and de novo design mainly by physics-based and ML-based methods.
John Quackenbush, PhD, Professor of Pediatrics and Human Genetics, University of Chicago; Professor Emeritus of Computational Biology and Bioinformatics, Harvard T.H. Chan School of Public Health
Professor of Pediatrics and Human Genetics
University of Chicago
John Quackenbush is Professor of Pediatrics and Human Genetics in the Division of Biological Sciences and the program in AI and Biological Complexity at the University of Chicago, a member of the University of Chicago Comprehensive Cancer Center, and Professor Emeritus at the Harvard T.H. Chan School of Public Health. John’s PhD was in Theoretical Physics, but a fellowship to work on the Human Genome Project led him through the Salk Institute, Stanford University, The Institute for Genomic Research (TIGR), Harvard in 2005, and UChicago in 2026. John’s research uses massive data to probe how many small genetic and other effects combine to influence our health and risk of disease. Key to his approach is modeling gene regulatory networks and understanding how these networks change between health and disease, over time, as a function of sex and gender, and between individuals. His more than 350 published papers have more than 107,000 citations, and his “NetZoo” software tools have tens of thousands of downloads. Among his honors is recognition in 2013 as a White House Open Science Champion of Change. In 2012, he founded Genospace, a precision medicine software company that was sold to Hospital Corporation of America in 2017. In 2022, he was elected to the National Academy of Medicine.
Santha Ramakrishnan, PhD, Vice President, Head, R&D Data Strategy and Governance, Bayer Pharmaceuticals
VP, Head, R&D Data Strategy and Governance
Bayer Pharmaceuticals
Santha is passionate about the effective use of data and enabling organizations for it, via strategy, people, technology, and operations. Her experience in life science R&D, informatics, and data comes from leading R&D data strategy and operations at Sanofi, developing informatics products at Monsanto, Ingenuity, and Certara, managing business units in Jubilant Biosys, and advising and enabling pharma clients at Deloitte.
Selvamurugan Ramamoorthy, Senior Principal Engineer, Data Engineering, Moderna
Senior Principal Engineer
Moderna
Selvamurugan Ramamoorthy is a Senior Principal Engineer at Moderna, specializing in enterprise database platforms, cloud data infrastructure, and resilient data architectures. His expertise spans data engineering, high availability, disaster recovery, performance optimization, and operational reliability in regulated enterprise environments. He is an IEEE Senior Member, a Fellow of the British Computer Society (BCS), and a Fellow of the Association for Project Management (APM). He also serves in a leadership role at DAMA Northeast, contributing to professional knowledge sharing and the advancement of data management practices. His professional interests include AI-ready data infrastructure, platform resilience, data governance, and trustworthy data systems supporting pharmaceutical innovation.
Brigitte E. Raumann, Product Manager, University of Chicago, Globus
Product Manager
University of Chicago, Globus
Brigitte Raumann is a Product Manager at Globus and led the effort to enable Globus support for management of protected research data, including PHI and CUI. As the Globus Privacy Officer, she continues to oversee the Globus compliance program and incident investigations. Brigitte has focused her career on providing researchers with the software tools and data they require to advance discovery. Her decades of experience span sectors as diverse as biotech, publishing, patent law, and academic clinical research. Brigitte Raumann earned her B.A. from the University of California, Berkeley and her Ph.D. in biochemistry from the Massachusetts Institute of Technology.
Judith Reece, PhD, Founder & Strategic Advisor, Reece Advisory Ltd.
Founder & Strategic Advisor
Reece Advisory Ltd
Judith Reece, PhD, is a life sciences strategist and independent adviser with more than 30 years of experience spanning academic medicine, pharmaceutical R&D and digital innovation. She has held senior leadership roles at AstraZeneca and GSK, including Executive Director of Corporate Strategy at AstraZeneca and Vice President of Digital, Data and AI Strategy for R&D at GSK. Her career began in academic medicine, including postdoctoral research at Harvard Medical School. Through Reece Advisory, Judith works with life sciences organisations to translate emerging science and technology into practical strategies that improve R&D productivity, strengthen decision-making and deliver meaningful value for patients. Her experience spans drug development strategy, portfolio management, digital transformation, AI adoption and the organisational changes required to embed innovation at scale. Judith has contributed to the development of eight marketed medicines and led strategic programmes delivering substantial enterprise value. She brings a distinctive perspective that combines scientific understanding, senior industry leadership and hands-on experience of navigating transformation in complex, regulated environments. Her particular interest is in moving beyond technological promise to demonstrate how AI and digital innovation can deliver measurable improvements in research, clinical development and patient outcomes.
Jeffrey A. Rosenfeld, PhD, Vice President, R&D, Foresee Genomics
Vice President, R&D
Foresee Genomics
Dr. Jeffrey Rosenfeld, PhD, MBA has extensive experience in genomics and bioinformatics. He is the author of over 40 scientific publications, a graduate-level textbook, and the recipient of a US patent. He received his undergraduate education at the University of Pennsylvania and his PhD in biology from NYU. He performed his doctoral research at the prestigious Cold Spring Harbor Laboratory. Over his 15-year career in genomics, he has worked on a wide range of biological and genetic projects including genetic association studies of schizophrenia, genomic testing of embryos for fertility treatments, gene patent litigation, and clinical cancer genome sequencing. For the past five years, he has been an Assistant Professor of Pathology and Laboratory Medicine and the head of the Bioinformatics Core at the Rutgers Cancer Institute. In this role, he has become very familiar with laboratory testing both for cancer and other genetic diseases. He has set up the computational infrastructure for multiple tumor sequencing panels as well as a clinical data warehouse. Dr. Rosenfeld is always at the leading edge of technology and is looking for the newest ideas that can be used for scientific research and diagnostics including single-cell techniques and long-read sequencing. Additionally, Dr. Rosenfeld has been sought out for his expertise as the head of Rosenfeld Consulting LLC. Clients come to him seeking advice regarding genomics, oncology, and laboratory testing. Due to his long tenure in the field and his knowledge of genomics as well as finance, he can give a clear assessment of the companies and their potential. Companies approach Dr. Rosenfeld looking for his expert-level genomics knowledge, industry insight, and management experience.
Natasha A. Sahr, PhD, Senior Director, Biostatistics, AI & Machine Learning Biometrics, Solid Biosciences, Inc.
Sr Dir Biostatistics
Solid Biosciences Inc
Taha Salim, PhD, Associate Director, In silico CMC, Sanofi
Associate Dir
Regeneron Pharmaceuticals Inc
Taha Salim is an experienced bioprocess engineer specializing in data science and scale-up technologies, with a particular emphasis on digital twins. He earned his PhD in Biomedical Engineering from the University of Houston, where he focused on host-pathogen interactions through in silico mathematical modeling and in vitro experimental testing. After completing his PhD, Taha undertook a Postdoctoral Fellowship and advanced to the role of Senior Scientist at Merck. In this capacity, he leveraged multivariate analytics and machine learning to enhance chemically defined nutrient feeds for CHO cell cultures and bioprocesses. Currently, he is a Staff Data Scientist within the Data Enablement and Analytics group at Regeneron Pharmaceuticals. In this role, he acts as a data science product owner and developer, creating AI/ML models and custom data science tools to support large molecule process development.
Philippe Sanseau, PhD, Executive Head, Global Biodata Coalition (GBC)
Executive Head
Global Biodata Coalition (GBC)
Dr. Philippe Sanseau, PhD, is the Executive Head of the Global Biodata Coalition. Philippe joined GBC in March 2026.Philippe obtained his PhD in France at the University of Rennes 1 before starting a post doctoral position at Cancer Research UK. He then joined GlaxoSmithKline (GSK) where he was most recently Senior Director. During his long tenure at GSK, Philippe led different bioinformatics and computational biology teams across different countries with a focus on analysing genetics and genomics data to support drug discovery and development for multiple therapeutic areas. He has published extensively in scientific journals and he has been a member of multiple funding committees and scientific advisory boards at a national and international level. Philippe has also been a key player in establishing and growing large and successful public-private scientific partnerships such as Open Targets.
Nicholas J. Sarlis, MD, PhD, FACP, CMO, CLEARA Biotech B.V.
Chief Medical Officer
CLEARA Biotech BV
Dr. Nicholas Sarlis is an accomplished physician-scientist with extensive expertise in oncology, hematology, and drug discovery and development. He currently serves as Chief Medical Officer at CLEARA Biotech B.V., while he additionally leads initiatives to integrate artificial intelligence and machine learning into clinical and translational research and the practice of precision medicine. Throughout his career, Dr. Sarlis has directed medical strategies for the launch of six global products across a total of nine indications and overseen the development of an additional eleven pipeline candidates. He has served as principal or associate investigator in thirty-eight clinical and translational studies and two disease registries, and has played a key role in supporting a biotech firm's transition from private to public ownership and its financing activities. Dr. Sarlis has represented organizations in joint drug co-development and commercialization committees with major pharmaceutical partners, and has frequently participated as a speaker or panelist at international scientific and industry conferences. His previous leadership roles include positions at Amplity Health, The Lynx Group, SELLAS Life Sciences, Incyte Corporation, and Sanofi, in addition to academic appointments at MD Anderson Cancer Center and the US National Institutes of Health. Dr. Sarlis holds M.D., Dr. Med. Sci., and Ph.D. degrees, has completed residency and fellowship training, maintains active licensure and board certification, and has demonstrated a strong ongoing commitment to professional development. He is an elected Fellow of several respected professional societies and is an author of over 140 publications, having received several awards recognizing his contributions to the field.
Fritz Sedlazeck, PhD, Associate Professor, Human Genome Sequencing Center, Baylor College of Medicine
Associate Professor, Human Genome Sequencing Ctr
Baylor College of Medicine
Dr. Fritz Sedlazeck is an Associate Professor at Baylor College of Medicine and an adjunct Associate Professor at Rice University. He is leading a research group since 2017 at the Human Genome Sequencing Centre at Baylor College of Medicine. His research focuses on developing computational methods to detect and analyze genomic variations with a focus on Structural Variations. Structural Variations are genomic events that manipulate multiple positions in a genome, which impact evolution, genomic disorders, regulation as well as play an important role in explaining multiple phenotypes. Dr. Sedlazeck groups focuses on the mechanisms of the formation of SV across multiple species and to improve our understanding how these complex alleles evolve and impact phenotypes. Over the past years, Dr. Sedlazeck lead multiple efforts from large scale short reads (e.g. Topmed, CCDG) to long reads (CARD, All of US) to study SV occurrence, impact and mechanism of SV.
Anu Sharma, Senior Principal Scientist/Senior Director, MRL BARDS Epidemiology RWE Capabilities and Analytics, Merck & Co., Inc.
Senior Principal Scientist and Senior Director
Merck
Anu Sharma is a Senior Principal Scientist and Real World Evidence platforms leader at Merck. She leads Data Sciences, Platform Strategy and Health Economic Modeling Initiatives within the MRL Biostatistics and Research Decision Sciences(BARDS) working with cross functional teams to leverage the value of real world data across the drug discovery, clinical development and commercialization lifecycle. Anu is a STEM leader, an AI enthusiast and avid industry speaker. With multiple accolades, she continues to strive towards saving patient lives and making world a healthier place.
Raman Singh, Head of AI and Data Platforms Operations, Takeda
Takeda Pharmaceuticals U.S.A., Inc.
Raman Singh is Head of AI & Data Platforms, Operations at Takeda, where he leads global teams running 25+ mission-critical AI and data platforms spanning data science, MLOps and Agentic AI. He is scaling a modern Lakehouse foundation across biopharmaceutical operations and extending it into the science itself, applying Agentic AI to molecule discovery, target identification and in-silico R&D. Before Takeda, Raman spent nearly nine years at Revvity (formerly PerkinElmer), most recently as Head of Enterprise Technology & Architecture. There he drove enterprise-wide Generative AI adoption, deploying large language models and intelligent automation that transformed critical processes. Earlier, as Head of Enterprise Architecture, he led cloud migration, modern data platforms and data governance programs. Raman believes the most durable advantage in life sciences is not any single model but the governed, interoperable platform on which every model can run.
Morten Sogaard, PhD, Senior Vice President, Astellas Innovation Lab
Senior Vice President
Astellas Innovation Lab
Morten Søgaard, PhD, is Senior Vice President and Head of Astellas Innovation Lab, where he oversees global R&D innovation initiatives focused on advancing emerging science and technologies through strategic partnerships and external collaboration. Previously, he led Research and Technical Operations at Astellas Gene Therapies. Before joining Astellas, Morten held several senior leadership positions at Pfizer, including Head of Target Sciences, Global Head of Genome Sciences, and Head of Search and Evaluation for Platform Technologies and Oncology. He also helped shape Pfizer's R&D strategies for AI, data, precision medicine, and emerging scientific technologies. Earlier in his career, Morten held research and technology leadership roles at Boehringer Ingelheim, AstraZeneca, and Pharmacia, spanning biologics, genomics, platform technologies, and research informatics. He holds a PhD in Biochemistry from the University of Copenhagen and completed postdoctoral research at Memorial Sloan Kettering Cancer Center.
Christopher Southan, PhD, Honorary Professor, Deanery of Biomedical Sciences, University of Edinburgh
Honorary Professor, Deanery of Biomedical Sciences
University of Edinburgh
Dr. Christopher Southan works at the interface between bioinformatics, cheminformatics, pharmacology and drug discovery. His current role as Honorary Professor at Edinburgh University was preceded by a Data Scientist role at Medicines Discovery Catapult, (2020-24) UK (working remotely from Sweden) preceded by being Owner and Principle Consultant at TW2 informatics in Göteborg, Sweden. In turn this was preceded by Senior Cheminformatian for the Edinburgh University BPS/IUPHAR Guide to Pharmacology database team 2013-18. Prior to this he set up TW2Informatics, engaging in patent data consulting for SureChem (2011-12) and the AstraZeneca Knowledge Engineering Program for testing and documenting Chemistry Connect (2009-11). During 2008-9, he coordinated the ELIXIR Database Provider Survey at the EBI, preceded by a Principle Scientist and Bioinformatics Team Leader position in AstraZeneca, Mölndal (2004-7) preceded by senior bioinformatics positions at Oxford Glycosciences Gemini Genomics and SmithKline Beecham. He has a PhD in Protein Chemistry from the Ludwig Maximillian University of Munich and a BSc Hons in Biochemistry from Dundee University (further information on LinkedIN).
Tejasvi Srigiriraju, Full Stack Developer, AbbVie
Full Stack Developer
AbbVie
Tejasvi is a full-stack developer at AbbVie, where she works with R&D teams to develop practical software solutions that support research across the biologics pipeline. With more than six years of experience in pharmaceuticals, she has contributed to workflow digitization, laboratory information management systems, and tools that help streamline research operations. With a background in computer science and a growing focus on generative AI, Tejasvi is interested in applying emerging technologies to solve real-world challenges and enable scientific teams. She is passionate about applying practical software and emerging AI capabilities to support research across the biologics pipeline.
Parthiban Srinivasan, PhD, Professor and Director, Center for AI in Medicine, Vinayaka Mission's Research Foundation, India
Professor and Director
Vinayaka Mission's Research Foundation
Parthiban Srinivasan, an experienced data scientist, earned his PhD from Indian Institute of Science, specializing in Computational Chemistry. After his PhD, he continued the research at NASA Ames Research Center (USA) and Weizmann Institute of Science (Israel). Then he worked at AstraZeneca in the area of Computer Aided Drug Design for Tuberculosis. Later, he headed informatics business units in Jubilant Biosys and then in GvkBio before he floated the company, Parthys Reverse Informatics and later an AI consultancy, Vingyani. Then he returned to academia as a Professor of Data Science at the Indian Institute of Science Education and Research, Bhopal. Currently, Parthiban is a Professor and Director at the Center for AI in Medicine, Vinayaka Missions Research Foundation, AV Medical College and Hospital, Puducherry, India
Anil Srivastava, President, Open Health Systems Laboratory (OHSL)
President
Open Health Systems Laboratory, Inc.
Anil Srivastava as head of Open Health Systems Laboratory (OHSL) located on the JHU Montgomery County Campus at US National Cancer Institute (NCI) in Rockville, MD, leads the ICKA: International Cancer Knowledge Alliance and ICTBioMed: International Consortium for Technology in Biomedicine beside serving as Special Volunteer, Radiation Research Program (RRP) and Member, Quantitive Imaging Network (QIN) International Liaison Committee at NCI. In the past, he has worked as an international program coordinator with NCI’s Center for Biomedical Informatics and Information Technology (NCI CBIIT) where he led the IUCRG: Indo-US Cancer Research Grid initiative which led to the creation of the National Cancer Grid in India. Later he served as senior advisor for life sciences with Internet2 (University Corporation for Advanced Internet Development) and Advisor to India’s National Knowledge Commission which established the direct fiber connection between the research and education network of India (National Knowledge Network) and United States (Internet2). He currently serves as Advisor, Biomedical Informatics for the Indian National Cancer Institute of the All India Institute for Medical Sciences (AIIMS), New Delhi, and Visiting Faculty and Consultant on Information Technology for Tata Memorial Hospital, Mumbai, India. As part of the collaboration between OHSL and Tata Memorial Hospital he advised on international procurement of the proton therapy facility and planning for the center of excellence and research for carbon ion therapy. He has been associated with the conception and planning of the Indian National Cancer Institute of AIIMS from the beginning. Previously, he was a member of Apple’s Advanced Technology Group. He continues his work as Advisor to the World Bank Group increasingly focusing on health systems and planning for non-communicable diseases treatment and research in LMICs (Lower and Middle Income Countries). In the past, he worked as a senior professional advisor with Booz-Allen & Hamilton in the Asia-Pacific region. He has several publications and research papers to his credit and has been a speaker at professional conferences (AACR, Accelerating Biology Symposium, BioIT, Indian Cancer Congress, Internet2, etc.). Biomedical informatics and establishing international collaboration in cancer research and treatment are his special field of interest and expertise. Prior to moving to the United States, he was the founding chief executive (1989-91) of NASSCOM: National Association of Software and Service Companies and founding director (1972-86) and head of Knowledge Engineering with Centre for Development of Instructional Technology.
Nagaraja "Sri" Srivatsan, CEO, Endpoint Clinical, Inc.
CEO
Endpoint Clinical, Inc.
Srivatsan has over thirty years of experience in growing businesses in the Digital, Data, AI, Analytics, IT, Product and Operations management areas across several industry verticals. Currently he is helping companies unlock exponential growth opportunities to scale their businesses by leveraging the power of AI. Previously as Chief Digital Officer for R&DS Technologies, IQVIA he was responsible for driving growth and leading product development and operations of R&DS Technologies. Prior to that, as Chief Growth Officer for EXL he oversaw the Sales & Marketing, Consulting and Strategy functions helping EXL become a Strategic digital transformation partner to its customers. Before that, as Venture partner, he grew Cognizant’s foray into Digital & Platforms. He identified, incubated and grew innovative digitally enabled ventures across the Healthcare & Life Sciences value chain. Early on, He was responsible for growing Cognizant’s Life Sciences business unit to be a Tier one provider. He has worked with the many of the top 50 global Life Sciences organizations providing them comprehensive end-to-end consulting, analytics, business process and IT solutions. He has provided strategic leadership in helping life sciences organizations leverage technology and the global delivery model to effectively transform their businesses. Srivatsan was recognized as the top 100 most inspiring people in the life sciences industry award by PharmaVOICE publication in 2010 and 2021. Srivatsan holds a bachelor's in electrical engineering from B.I.T.S. in India and a master's degree in electrical engineering & computer science from Northwestern University.
Eric Stahlberg, PhD, Executive Administrative Director, Institute for Data Science in Oncology, MD Anderson Cancer Center
Executive Administrative Director
MD Anderson Cancer Center
Dr. Eric Stahlberg is the Executive Administrative Director, Institute for Data Science in Oncology, at MD Anderson Cancer Center. Previously he directed cancer data science initiatives at the Frederick National Laboratory, having led and launched several initiatives at the lab. He was instrumental in establishing the Frederick National Laboratory’s high-performance computing initiative and in assembling scientific teams across multiple, complex organizations to advance predictive oncology. Stahlberg first joined the Frederick National Laboratory in 2011 to form and direct the National Cancer Institute’s Center for Cancer Research Bioinformatics Core, which helped build intramural research collaborations between the national laboratory and the National Cancer Institute. Since then, Stahlberg has played a leadership role in many key partnerships, including a major collaboration between the National Cancer Institute and the Department of Energy. Under the Joint Design of Advanced Computing Solutions for Cancer (JDACS4C), the National Cancer Institute and Department of Energy are accelerating progress in precision oncology and computing. The collaboration is rooted in three major national initiatives; the Precision Medicine Initiative, the National Strategic Computing Initiative, and the Cancer Moonshot. He has helped lead initiatives to transform data management approaches at the lab as well as more recently leading program efforts exploring the application biomedical digital twins for cancer applications. Stahlberg has spearheaded the Frederick National Laboratory’s contributions to a number of JDACS4C projects, including ATOM and CANDLE. He helped launch the annual meeting series, Frontiers in Predictive Oncology and Computing, and co-organizes the annual Computational Approaches for Cancer and HPC Applications of Precision Medicine workshops. In 2017, he was recognized as one of FCW‘s Federal 100. Stahlberg holds a Ph.D. in computational chemistry from The Ohio State University.
Deanne M.Taylor, PhD, Director, Bioinformatics & Research Associate Professor, Biomedical & Health Informatics, Children's Hospital of Philadelphia
Dir Bioinformatics & Research Assoc Prof
Childrens Hospital of Philadelphia
Deanne M. Taylor, PhD, is Director of Bioinformatics in the Department of Biomedical and Health Informatics at Children’s Hospital of Philadelphia and Research Associate Professor of Pediatrics at the University of Pennsylvania’s Perelman School of Medicine. Her research combines computational biology, machine learning, and biomedical data integration to investigate development and disease. She develops knowledge graphs and analytical methods that connect diverse biomedical datasets to support scientific discovery. Dr. Taylor earned her PhD in Biophysics from the University of Michigan.
André A. R. Teixeira, PhD, Senior Director, Antibody Platform, Institution for Protein Innovation
Senior Director
Institute for Protein Innovation
Andre Teixeira is a pharmacist and biochemist and currently serves as the Senior Director of the Antibody Platform at the Institute for Protein Innovation (IPI) in Boston. He leads an end-to-end, high-throughput discovery engine spanning antigen engineering, yeast display, NGS analytics, antibody expression and developability profiling—delivering 250+ successful campaigns annually. His team builds next-generation synthetic libraries, nanobodies, and biparatopic/bispecific antibodies and shares reagents broadly to accelerate research and therapeutics. Interests include multipass and single-pass membrane targets, receptor clustering biology, bispecifics, biparatopics, antibody, and nanobody engineering.
Thomas George Thomas, Senior Data Engineer, Platform Engineering, Montai Therapeutics
Sr Data Engineer
Montai Therapeutics
Thomas George Thomas is a Senior Data and ML Platform Engineer at Montai Therapeutics, where he drives innovation in data infrastructure to accelerate drug discovery through advanced analytics and machine learning. With over nine years of experience spanning big data engineering, MLOps, and cloud computing, he designs and implements end-to-end solution architectures encompassing CI/CD, data, and ML pipelines. Thomas specializes in data engineering, warehousing, modeling, and analytics engineering—building scalable, automated systems that transform complex life science data into actionable insights. At Montai, he leads initiatives to unify chemoinformatics and bioscience datasets into a robust data mesh, enabling seamless data integration and value delivery across scientific and computational teams. His career spans roles in healthcare technology and academic research, with a consistent focus on automation, performance optimization, cross-functional data collaboration and translating data into discovery.
Vas Vasiliadis, Chief Customer Officer, University of Chicago, Globus
Chief Customer Officer
University of Chicago, Globus
Vas leads the customer team for Globus, an innovative software-as-a-service for research data management, developed and operated by the University of Chicago. He works with current and prospective users to grow adoption of the service and make it self-sustaining. Vas is also a lecturer in the Master's Program in Computer Science, where he teaches courses on Cloud Computing and Product Management. Vas has 30 years of experience in operational and consulting roles, spanning strategy, marketing, and technology. He has nurtured early-stage companies into successful businesses and consulted with companies on a wide range of strategic issues. Vas holds an MBA from the Ross School of Business at the University of Michigan, Ann Arbor, and a BS in Electrical Engineering from the University of the Witwatersrand in South Africa.
John Zhao Yang Wang, Director, AI Innovation, Shanghai Henlius Biotech Co. Ltd.
Dir AI Innovation
Shanghai Henlius Biotech Co Ltd
John Wang is Head of AI Innovation at Shanghai Henlius Biotech, where he leads the application of AI across drug discovery and development, regulatory affairs, CMC and manufacturing, commercialization, and enterprise operations. He brings more than 12 years of experience spanning pharmaceuticals, artificial intelligence, and business transformation. Previously, John served as Head of AI and Digital Innovation at WuXi Biologics and held roles at multinational pharmaceutical companies and AI technology startups. He has built AI capabilities and cross-functional teams from the ground up, with a focus on moving promising technologies into everyday use. His work connects scientific and business priorities with practical AI implementation, helping organizations scale adoption, retain institutional knowledge, and deliver measurable business value. His current focus is on the leadership, governance, and organizational capabilities needed to move AI beyond isolated pilots and into sustained use across biopharma R&D.
Elizabeth Worthey, PhD, Director, Center for Computational Genomics & Data, University of Alabama Birmingham
Director
Univ Of Alabama Birmingham
Dr. Liz Worthey is an Associate Professor of Genetics at UAB, Director of the Center for Computational Genomics and Data Science, and Associate Director of the Hugh Kaul Precision Medicine Institute. With more than 25 years of experience in human disease translational research and clinical diagnostics, her work focuses on developing and applying omic and computational approaches to understand the molecular mechanisms underlying human disease. Her research integrates these methods to identify disease-causing and modifying variation, explain differences in clinical presentation and progression, and uncover opportunities for therapeutic intervention. A central focus of her work is moving beyond molecular diagnosis to understand how genetic and other biological factors influence disease outcomes and treatment response, with the ultimate goal of enabling more precise, individualized care for people with rare and poorly understood conditions.
Lei Xie, PhD, Professor, Pharmaceutical & Biomedical Sciences, Northeastern University; Adjunct Profession, Computer Science, The City University of New York; CSO, Dark Matter Therapeutics, Inc.
Prof
Northeastern Univ
Dr. Lei Xie is currently a professor in Pharmaceutical Sciences in Northeastern University and an adjunct profession in Computer Science at The City University of New York. He is also Chief Scientific Officer of Dark Matter Therapeutics, Inc. His research focuses on developing new methods in artificial intelligence, machine learning, systems biology, and biophysics for multi-scale modeling of drug actions and causal genotype-phenotype associations, and applying them to drug repurposing, drug discovery and precision medicine.
Donghui Yan, PhD, Senior Scientist, Quantitative Medicine and Genomics, AbbVie
Sr Scientist
AbbVie Inc
Donghui Yan, PhD, is a Senior Scientist at AbbVie specializing in artificial intelligence and computational biology for biopharmaceutical research. His work focuses on integrating scientific knowledge and diverse data to support biological discovery and data-driven decision-making, with applications in cell engineering and biologics development. He received his PhD in Computer Science from Carnegie Mellon University.

Register

Conference Tracks

T1: Data Platforms & Storage Infrastructure